Effect of combination of radiotherapy and docetaxel on Cripto-1, β-catenin and DBC1 expression in breast cancer patients

Abstract

Among all cancer types, blood cancer tops in total number of estimated cases and ranks fourth in fatalities caused by cancer. Early diagnosis and treatment, particularly for breast cancer, may prevent such fatalities to some extent. In this context, here, we have explored the effect of docetaxel combined with radiotherapy on cripto-1, β-catenin and DBC1 expression in breast cancer patients. In this study, a total of 80 breast cancer patients treated in our hospital from May 2017 to May 2020 were selected and divided into 40 patients each in radiotherapy treatment group and docetaxel combination group according to complete randomization method. Patients in both groups were treated with conventional basic therapy, patients with breast cancer were treated with radiotherapy in the radiotherapy treatment group, and patients with breast cancer were treated with docetaxel and radiotherapy in the docetaxel combination group. Serum samples were analyzed by ELISA for tumor markers: carbohydrate antigen CA15-3 (CA15-3), glycoprotein CA125 (CA125), carcinoembryonic antigen (CEA); the protein Cripto-1 (Cripto-1), β-catenin, deletion gene 1 (DBC1) were detected by fluorescence quantitative PCR method (qPCR); clinical efficacy as well as adverse effects were evaluated and the cycle of breast cancer patient survival was counted. Compared with radiotherapy treatment group, the levels of CA15-3, CA125, CEA, Cripto-1, β-catenin and DBC1 in docetaxel combination group were significantly decreased, with statistically significant difference (P <0.05). The overall response rate for breast cancer treatment was higher in the docetaxel combination group compared with the radiotherapy treatment group alone (P <0.05). Median overall survival and survival rate were higher in the docetaxel combination group compared with the radiotherapy treatment group alone (P <0.05). The combination of docetaxel and radiotherapy significantly improved the clinical symptoms of breast cancer patient, the expression level of Cripto-1, β-catenin and DBC1 in patients, which promote the physical recovery of breast cancer patients, prolong the survival cycle, reduce the mortality rate, and have a better effect.